During a presentation in Taipei on Monday the CEO of US therapeutics company Receptor BioLogix Dr. Michael Shepard outlined his company's anti-cancer drug development pipeline.

Shepard's talk focused on the company's new drug Herstatin designed to act on tumor cells that overexpress HERS-2—human epidermal growth factor receptor 2.

At this early stage of drug testing Herstatin is showing effectiveness on a wider range of cancers than the earlier-generation anti-cancer HERS-2 drug Herceptin co-discovered by Shepard and now produced by US-based Genentech mainly for breast cancer treatment.